← Back to Search

Ocufolin for Eye Conditions

N/A
Recruiting
Led By Jianhua Wang, MD, PhD
Research Sponsored by University of Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Self-reported normal healthy subjects
Has clear corneas and crystalline lens
Must not have
Has an active ocular disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will help researchers understand if these devices can be used to study different eye conditions and if Ocufolin can help improve vision.

Who is the study for?
This trial is for adults with clear vision of at least 20/80 who have conditions like dementia, MS, dry eye, diabetic retinopathy, or near-sightedness. They must be able to undergo advanced eye imaging and have had no recent eye surgery or injury. People with active ocular diseases or intolerance to bright light during imaging cannot participate.
What is being tested?
The study first observes the eyes using technologies like OCT and RFI. Then it tests if taking Ocufolin—a medical food—over six months can change the eyes' condition in people with various ophthalmic disorders compared to normal healthy subjects.
What are the potential side effects?
Since Ocufolin is an over-the-counter medical food rather than a drug, specific side effects are not listed; however, any potential adverse reactions related to its intake will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I consider myself to be in good health.
Select...
My corneas and lens are clear.
Select...
I have a specific genetic mutation and mild to moderate eye blood vessel issues.
Select...
I have not had eye surgery or an injury in the last 6 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have an ongoing eye condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Conjunctival vasculature by functional slit-lamp (FSLB)
Corneal epithelial thickness
Retinal microstructure using OCT.
+2 more
Secondary study objectives
Conjunctival blood flow velocity by functional slit-lamp (FSLB)
Retinal blood flow velocity by retinal function imager (RFI)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Interventional Phase - Ocufolin GroupExperimental Treatment1 Intervention
Participants in this group will receive the Ocufolin medical food for 6 months.
Group II: Observational Phase GroupActive Control1 Intervention
Participants in this group will be studied and followed up for 1-2 years.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ocufolin
2017
N/A
~30

Find a Location

Who is running the clinical trial?

University of MiamiLead Sponsor
955 Previous Clinical Trials
423,853 Total Patients Enrolled
1 Trials studying Diabetic Retinopathy
3,000 Patients Enrolled for Diabetic Retinopathy
Jianhua Wang, MD, PhDPrincipal InvestigatorBascom Palmer Eye Institute, University of Miami, Miami, FL
4 Previous Clinical Trials
161 Total Patients Enrolled

Media Library

Ocufolin Clinical Trial Eligibility Overview. Trial Name: NCT03135327 — N/A
Diabetic Retinopathy Research Study Groups: Interventional Phase - Ocufolin Group, Observational Phase Group
Diabetic Retinopathy Clinical Trial 2023: Ocufolin Highlights & Side Effects. Trial Name: NCT03135327 — N/A
Ocufolin 2023 Treatment Timeline for Medical Study. Trial Name: NCT03135327 — N/A
Diabetic Retinopathy Patient Testimony for trial: Trial Name: NCT03135327 — N/A
~502 spots leftby Dec 2026